Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2021 - Issue
Submit an article Journal homepage
102
Views
3
CrossRef citations to date
0
Altmetric
Clinical Trial Report

A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD

Juthaporn Cowan1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6648-5109View further author information
ORCID Icon,
Sunita Mulpuru1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaORCID Iconhttps://orcid.org/0000-0001-6214-0613View further author information
ORCID Icon,
Sara J Abdallah2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
,
Anchal Chopra3 Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, Ontario, CanadaORCID Iconhttps://orcid.org/0000-0003-1250-7485View further author information
ORCID Icon,
Andrew Purssell1 Department of Medicine, University of Ottawa, Ottawa, Ontario, CanadaView further author information
,
Michaeline McGuinty1 Department of Medicine, University of Ottawa, Ottawa, Ontario, CanadaView further author information
,
Gonzalo G Alvarez1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
,
Antonio Giulivi2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;4 Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, CanadaView further author information
,
Vicente Corrales-Medina1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
,
Derek MacFadden1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
,
Loree Boyle1 Department of Medicine, University of Ottawa, Ottawa, Ontario, CanadaView further author information
,
Delvina Hasimja1 Department of Medicine, University of Ottawa, Ottawa, Ontario, CanadaView further author information
,
Kednapa Thavorn2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;5 School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada;6 Institute for Clinical Evaluative Sciences, Toronto, Ontario, CanadaView further author information
,
Ranjeeta Mallick2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
,
Shawn D Aaron1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
&
D William Cameron1 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;2 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaView further author information
 show all
Pages 3275-3284 | Published online: 03 Dec 2021

References

  • Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
  • GOLD. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease - GOLD; 2017. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed July 6, 2017.
  • Zhang Y, Morgan RL, Alonso-Coello P, et al. A systematic review of how patients value COPD outcomes. Eur Respir J. 2018;52(1):1800222. doi:10.1183/13993003.00222-2018
  • Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
  • Martinez FJ, Calverley PMA, Goehring U-M, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866. doi:10.1016/S0140-6736(14)62410-7
  • Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi:10.1164/rccm.200707-973OC
  • Hartung H-P, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158:23–33. doi:10.1111/j.1365-2249.2009.04024.x
  • Leitao Filho FS, Ra SW, Mattman A, et al. Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res. 2018;19(1):30. doi:10.1186/s12931-018-0733-z
  • Leitao Filho FS, Won RS, Mattman A, et al. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2017;140(4):1164–1167.e6. doi:10.1016/j.jaci.2017.01.046
  • Leitao Filho FS, Mattman A, Schellenberg R, et al. Serum IgG levels and risk of COPD hospitalization: a pooled meta-analysis. Chest. 2020;158(4):1420–1430. doi:10.1016/j.chest.2020.04.058
  • Cowan J, Gaudet L, Mulpuru S, et al. A retrospective longitudinal within-subject risk interval analysis of immunoglobulin treatment for recurrent acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2015;10(11):e0142205. doi:10.1371/journal.pone.0142205
  • McCullagh BN, Comellas AP, Ballas ZK, Newell JD, Zimmerman MB, Azar AE. Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS One. 2017;12(2):e0172437. doi:10.1371/journal.pone.0172437
  • Cowan J, Mulpuru S, Aaron S, et al. Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations. Pilot Feasibility Stud. 2018;4(1):135. doi:10.1186/s40814-018-0327-z
  • Bonilla FA. Pharmacokinetic s of Immunoglobulin administered via Intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28(4):803–819. doi:10.1016/j.iac.2008.06.006
  • Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-3
  • Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25–27. doi:10.1016/S0954-6111(06)80166-6
  • Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71(6):493–500. doi:10.1136/thoraxjnl-2015-207782
  • Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a once-daily inhaled Anticholinergic Bronchodilator. Ann Intern Med. 2005;143(5):317. doi:10.7326/0003-4819-143-5-200509060-00007
  • Xie F, Pullenayegum E, Gaebel K, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98–105. doi:10.1097/MLR.0000000000000447
  • Luthra R, Quimbo R, Iyer R, Luo M. An analysis of intravenous immunoglobin site of care: home versus outpatient hospital. Am J Pharm Benefits. 2014;6(2):e41–e49.
  • Le Masson G, Solé G, Desnuelle C, et al. Home versus hospital immunoglobulin treatment for autoimmune neuropathies: a cost minimization analysis. Brain Behav. 2018;8(2):e00923. doi:10.1002/brb3.923
  • Wen L, Krauss-Etschmann S, Petersen F, Yu X. Autoantibodies in chronic obstructive pulmonary disease. Front Immunol. 2018;9:66. doi:10.3389/fimmu.2018.00066
  • Liang Z, Wang F, Zhang D, et al. Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation. J Thorac Dis. 2020;12(6):3085–3100. doi:10.21037/jtd-20-545
  • Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American Academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2012;130(3):S1–S24. doi:10.1016/j.jaci.2012.07.002
  • Mathioudakis AG, Sivapalan P, Papi A, Vestbo J. The disEntangling Chronic Obstructive pulmonary Disease exacerbations clinical trials NETwork (DECODE-NET): rationale and vision. Eur Respir J. 2020;56(1):1. doi:10.1183/13993003.00627-2020
  • Mathioudakis AG, Moberg M, Janner J, Alonso-Coello P, Vestbo J. Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. ERJ Open Res. 2019;5(2):00072–02019. doi:10.1183/23120541.00072-2019

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.